The HELP system for the treatment of atherothrombotic disorders: a review.
Given the importance of atherothrombotic disorders for the public health system, and the known limitations of conventional treatment on one hand and the compelling biochemical evidence and long-term safety of HELP (Heparin-mediated Extracorporeal LDL/Fibrinogen Precipitation) apheresis on the other hand, this approach provides a most valuable tool for further medical research and treatment of the various atherothrombotic and microcirculatory disorders. The present contribution reviews the recent developments in chronic and single application of apheresis in cardiology with particular emphasis on the newly discovered therapeutic possibilities for myocardial infarction, stroke, and after coronary artery bypass grafting.
Jaeger
Beate Roxane
BR
Institute of Clinical Chemistry, Klinikum der Universität München, München, Germany. drbjaeger@web.de
D011232:Chemical Precipitation; D003324:Coronary Artery Disease / Q000628:therapy; D005112:Extracorporeal Circulation; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy; D010956:Plasmapheresis / Q000379:methods*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D020521:Stroke / Q000628:therapy; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D008077:Lipoproteins, LDL; D005340:Fibrinogen; D006493:Heparin